• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pharmacol Rep . In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta

tetano

Editor, Senior Moderator
Pharmacol Rep


. 2021 Feb 20.
doi: 10.1007/s43440-021-00233-3. Online ahead of print.
In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis


Hikmat Permana[SUP] 1 [/SUP], Ian Huang[SUP] 2 [/SUP], Aga Purwiga[SUP] 2 [/SUP], Nuraini Yasmin Kusumawardhani[SUP] 3 [/SUP], Teddy Arnold Sihite[SUP] 3 [/SUP], Erwan Martanto[SUP] 3 [/SUP], Rudi Wisaksana[SUP] 4 [/SUP], Nanny Natalia M Soetedjo[SUP] 5 [/SUP]



Affiliations

Abstract

Background and aims: The idea of treating COVID-19 with statins is biologically plausible, although it is still controversial. The systematic review and meta-analysis aimed to address the association between the use of statins and risk of mortality in patients with COVID-19.
Methods: Several electronic databases, including PubMed, SCOPUS, EuropePMC, and the Cochrane Central Register of Controlled Trials, with relevant keywords up to 11 November 2020, were used to perform a systematic literature search. This study included research papers containing samples of adult COVID-19 patients who had data on statin use and recorded mortality as their outcome of interest. Risk estimates of mortality in statin users versus non-statin users were pooled across studies using inverse-variance weighted DerSimonian-Laird random-effect models.
Results: Thirteen studies with a total of 52,122 patients were included in the final qualitative and quantitative analysis. Eight studies reported in-hospital use of statins; meanwhile, the remaining studies reported pre-admission use of statins. In-hospital use of statin was associated with a reduced risk of mortality (RR 0.54, 95% CI 0.50-0.58, p < 0.00001; I[SUP]2[/SUP]: 0%, p = 0.87), while pre-admission use of statin was not associated with mortality (RR 1.18, 95% CI 0.79-1.77, p = 0.415; I[SUP]2[/SUP]: 68.6%, p = 0.013). The funnel plot for the association between the use of statins and mortality were asymmetrical.
Conclusion: This meta-analysis showed that in-hospital use of statins was associated with a reduced risk of mortality in patients with COVID-19.

Keywords: COVID-19; In-hospital; Mortality; Pre-admission; SARS-CoV-2; Statins.
 
Back
Top Bottom